Dr. Betul Oran, MD
Claim this profileM D Anderson Cancer Center
Area of expertise
Acute Myeloid Leukemia
Betul Oran, MD has run 4 trials for Acute Myeloid Leukemia. Some of their research focus areas include:
Acute Myelogenous Leukemia
Betul Oran, MD has run 3 trials for Acute Myelogenous Leukemia. Some of their research focus areas include:
Affiliated Hospitals
M D Anderson Cancer Center
Clinical Trials Betul Oran, MD is currently running
Reduced-Dose Cyclophosphamide
for Leukemia After Stem Cell Transplant
The goal of this clinical trial is to determine the effectiveness of Reduced Dose Post-Transplant Cyclophosphamide (PTCy) in patients with hematologic malignancies after receiving an HLA-Mismatched Unrelated Donor (MMUD) . The main question\[s\] it aims to answer are: * Does a reduced dose of PTCy reduce the occurrence of infections in the first 100 days after transplant? * Does a reduced dose of PTCy maintain the same level of protection against Graft Versus Host Disease (GvHD) as the standard dose of PTCy?
Recruiting
1 award
Phase 2
Venetoclax + Azacitidine
for Acute Myeloid Leukemia
This phase II trial studies how well venetoclax and azacitidine work for the treatment of acute myeloid leukemia after stem cell transplantation. Venetoclax may stop the growth of cancer cells by blocking BCL-2, a protein needed for cancer cell survival. Chemotherapy drugs, such as azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving venetoclax and azacitidine after a stem cell transplant may help control high risk leukemia and prevent it from coming back after the transplant.
Recruiting
3 awards
Phase 2
23 criteria
More about Betul Oran, MD
Clinical Trial Related
9 years of experience running clinical trials · Led 6 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Betul Oran, MD has experience with
- Azacitidine
- Venetoclax
- Allogeneic Cytomegalovirus-Specific Cytotoxic T Lymphocytes
- MT-401
- ASTX727
- Donor Lymphocyte Infusion
Breakdown of trials Betul Oran, MD has run
Acute Myeloid Leukemia
Acute Myelogenous Leukemia
Acute Lymphoblastic Leukemia
Biphenotypic Leukemia
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Betul Oran, MD specialize in?
Betul Oran, MD focuses on Acute Myeloid Leukemia and Acute Myelogenous Leukemia. In particular, much of their work with Acute Myeloid Leukemia has involved HLA positive patients, or patients who are HLA-A negative.
Is Betul Oran, MD currently recruiting for clinical trials?
Yes, Betul Oran, MD is currently recruiting for 2 clinical trials in Houston Texas. If you're interested in participating, you should apply.
Are there any treatments that Betul Oran, MD has studied deeply?
Yes, Betul Oran, MD has studied treatments such as Azacitidine, Venetoclax, Allogeneic Cytomegalovirus-Specific Cytotoxic T lymphocytes.
What is the best way to schedule an appointment with Betul Oran, MD?
Apply for one of the trials that Betul Oran, MD is conducting.
What is the office address of Betul Oran, MD?
The office of Betul Oran, MD is located at: M D Anderson Cancer Center, Houston, Texas 77030 United States. This is the address for their practice at the M D Anderson Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.